Over the past five years, Gundry MD Bio Complete 3 has transformed how people approach digestive health, making it easier than ever to combat common gut health issues.†* Continue Reading Gundry ...

Bio Complete 3: A Best-Selling Triple-Biotic Gut Health Blend From Gundry MD LOS ANGELES, Sept. 27, 2024 /PRNewswire/ -- Gundry MD ® is thrilled to announce the 5th anniversary of its ...

LOS ANGELES, Sept. 27, 2024 /PRNewswire/ -- Gundry MD ® is thrilled to announce the 5th anniversary of its revolutionary gut health supplement, Bio Complete 3™. This product has set a new ...

Archroma unveils the NTR Printing System, the “first” commercially viable bio-based pigment printing solution that uses ...

Annovis Bio ... Buy rating due to a combination of factors regarding the progress of Annovis Bio’s lead drug candidate, buntanetap. The FDA’s clearance for Annovis Bio to advance into Phase 3 ...

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The ...

Bio-Techne Corporation TECH is set to release its first-quarter fiscal 2025 results on Oct. 30, before the opening bell. The ...

See Full Bio ... a 58.3% chance of a U.S. recession within the next 12 months. In this volatile and unpredictable market, Bank of America recently compiled a list of their best stocks to buy ...

As global markets experience shifts, with small-cap indices like the Russell 2000 and S&P MidCap 400 outperforming, investors are increasingly turning their attention to smaller companies for ...

Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC. Find out my recommendation on ...

On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock.